ApprovalTrail

Approval · Notice of Compliance 13700 · 2012

DIFFERIN: Notice of Compliance 13700

Issued October 3, 2012

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
13700
Date
October 3, 2012
Company
Galderma Canada Inc.Toronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Alternate manufacturing process for the synthesis of the drug substance
Therapeutic class
Acne Therapy

Products in this notice

BrandDINStatus today
DIFFERINNot yet assigned—
DIFFERIN XPNot yet assigned—

Medicinal ingredients